Emergent BioSolutions Inc. has inked another deal with fellow Gaithersburg biotech Novavax Inc. — this time, for its seasonal flu vaccine.
The agreement means Emergent (NYSE: EBS) will develop and manufacture NanoFlu, the influenza vaccine which Novavax (NASDAQ: NVAX) successfully pushed through phase 3 clinical trials in a critical win announced March 24. It also comes just a few weeks after the two companies teamed up to get a COVID-19 vaccine to the clinic in the race against the pandemic.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.